)
)
)
ENYO Pharma
ENYO Pharma is a clinical-stage biopharma with extensive phase I/II clinical data (11 completed/underway clinical studies; 400+ subjects) for Vonafexor and EYP651. ALPESTRIA-1, a Phase 2 study in Alport Syndrome, has completed enrollment and full results will be available at JPM 2026. The proof-of-concept Phase 2 trial in Alport demonstrated an improvement in eGFR that persisted after drug withdrawal. This is the second clinical study where this effect was observed.
ADPKD preclinical data will be available under CDA. Clinical work with EYP651 has started this year and can also be discussed.
Address
LYONFrance
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)